Notably, current therapies for IBD include antibodies that target IL‐23 either by blocking the activity of IL‐12p40, a subunit of both IL‐12 and IL‐23, or blocking solely IL‐23 with antibodies targeting the IL‐23p19 subunit [124]. The gene discussed is IL23A; the disease is inflammatory bowel disease.